Arvinas (ARVN) Cash from Investing Activities (2017 - 2026)
Arvinas' (ARVN) quarterly Cash from Investing Activities came in at $13.7 million in Q1 2026, down 80.29% year-on-year from $69.5 million in Q1 2025, and down 90.6% quarter-over-quarter from $145.8 million in Q4 2025.
Arvinas (ARVN) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Arvinas' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at $13.7 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 80.29% year-over-year to $13.7 million in Q1 2026; TTM through Mar 2026 was $351.8 million, a 51.64% increase from a year earlier, with the FY2025 full-year figure at $407.6 million, up 1074.64% from the prior year.
- Cash from Investing Activities fell to $13.7 million in Q1 2026 per ARVN's latest filing, from $145.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $145.8 million in Q4 2025 and bottomed at -$127.8 million in Q1 2024.
- The 5-year median for Cash from Investing Activities is $63.5 million (2025), against an average of $53.1 million.
- Biggest YoY gain for Cash from Investing Activities was 1511.63% in 2023; the steepest drop was 376.8% in 2023.
- Year by year, Cash from Investing Activities stood at $19.4 million in 2022, then plunged by 376.8% to -$53.7 million in 2023, then surged by 284.17% to $98.9 million in 2024, then jumped by 47.42% to $145.8 million in 2025, then sank by 90.6% to $13.7 million in 2026.
- Per Business Quant, the three latest ARVN Cash from Investing Activities figures stand at $13.7 million (Q1 2026), $145.8 million (Q4 2025), and $63.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Arvinas | 529.92 Mn | -84.98 Mn | - | 13.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.70 Mn |
| Mar 31, 2026 | 13.70 Mn |
| Dec 31, 2025 | 145.80 Mn |
| Dec 31, 2025 | 145.80 Mn |
| Sep 30, 2025 | 63.50 Mn |
| Sep 30, 2025 | 63.50 Mn |
| Jun 30, 2025 | 128.80 Mn |
| Jun 30, 2025 | 128.80 Mn |
| Mar 31, 2025 | 69.50 Mn |
| Mar 31, 2025 | 69.50 Mn |
| Dec 31, 2024 | 98.90 Mn |
| Dec 31, 2024 | 98.90 Mn |
| Sep 30, 2024 | 50.50 Mn |
| Sep 30, 2024 | 50.50 Mn |
| Jun 30, 2024 | 13.10 Mn |
| Jun 30, 2024 | 13.10 Mn |
| Mar 31, 2024 | -127.80 Mn |
| Mar 31, 2024 | -127.80 Mn |
| Dec 31, 2023 | -53.70 Mn |
| Dec 31, 2023 | -53.70 Mn |